Kinarus-Logo_RGB.jpg
Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update
February 21, 2023 01:00 ET | Kinarus Therapeutic Holding AG
KINFAST is evaluating KIN001 for reduction in severity and duration of Covid-19 symptomsKINFAST is actively enrolling in Germany/Switzerland Basel, Switzerland, 20 February 2023. Kinarus Therapeutics...
Kinarus-Logo_RGB.jpg
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan
January 17, 2023 01:00 ET | Kinarus Therapeutic Holding AG
 KIN001 reduced fibrotic damage of the lung in a preclinical fibrosis modelPotential as an effective oral therapy for Idiopathic Pulmonary Fibrosis (IPF)Phase 2 clinical trial in IPF patients in...
Kinarus-Logo_RGB.jpg
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5
December 06, 2022 01:00 ET | Kinarus Therapeutic Holding AG
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5 Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg and Kinarus report...
Kinarus-Logo_RGB.jpg
Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001
November 22, 2022 01:00 ET | Kinarus Therapeutic Holding AG
Method-of-use-patent covers KIN001 in ophthalmic diseasesFurther strengthens already granted KIN001 US composition of matter patent Basel, Switzerland, 22 November 2022. Kinarus Therapeutics...
Kinarus-Logo_RGB.jpg
Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China
November 16, 2022 01:00 ET | Kinarus Therapeutic Holding AG
Kinarus to explore partnerships in China to fund Phase 2 clinical trials of KIN001 and explore further business opportunitiesMultiple opportunities for KIN001 in indications with high unmet need are...
Kinarus-Logo_RGB.jpg
Kinarus Therapeutics Provides Strategic Update
November 04, 2022 02:00 ET | Kinarus Therapeutic Holding AG
Exploring financial and strategic options to fund Phase 2 trials of KIN001 in wet age-related macular degeneration and idiopathic pulmonary fibrosisKINFAST phase 2 clinical trial of KIN001 in mild to...
Kinarus-Logo_RGB.jpg
Kinarus Therapeutics Announces Discontinuation of the Phase 2 KINETIC Study of KIN001 in Hospitalized COVID-19 Patients Following a Prespecified Interim Analysis of Efficacy and Safety
September 30, 2022 01:00 ET | Kinarus Therapeutic Holding AG
KINETIC, a Phase 2 clinical study of KIN001, an oral drug combination, to be discontinued following recommendation of the DSMBKIN001 was shown to be safe and well toleratedEnrollment in the Phase 2...
Kinarus-Logo_RGB.jpg
Kinarus Therapeutics Reports H1 2022 Financial Results and Provides Corporate Update
August 31, 2022 01:00 ET | Kinarus Therapeutic Holding AG
Interim data from Phase 2 KINETIC clinical trial of KIN001 to treat hospitalized COVID-19 patients expected in Q3 2022First patient dosed with in Phase 2 KINFAST clinical trial with ambulatory...
Kinarus-Logo_RGB.jpg
Kinarus Therapeutics initiates KIN001 Phase II KINFAST clinical trial in COVID-19 outpatients
August 29, 2022 01:00 ET | Kinarus Therapeutic Holding AG
KINFAST to evaluate ability of KIN001 to reduce severity and duration of symptoms in ambulatory COVID-19 patientsInterim data from ongoing Phase 2 KINETIC trial in hospitalized Covid-19 patients...
Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19
August 22, 2022 01:05 ET | Kinarus Therapeutic Holding AG
KIN001 has synergistic antiviral, anti-inflammatory activity, and anti-fibrotic mechanismsPhase 2 trials of KIN001 in hospitalized and ambulatory COVID-19 patients ongoingInterim data from Phase 2...